top of page
News at Epineuron


First Patient in REGAIN | Dr. Ming Chan, Dr. Adil Ladak, Dr. Adrian Battiston, Katelyn So, Yumna Irfan

Epineuron Announces Enrollment of its First Patient in REGAIN™

August 30, 2023

Epineuron jumpstarts REGAIN™, a pivotal trial evaluating its bioelectronic device to treat nerve damage, with the enrollment of its first patient. 

Epineuron’s efforts to create a pain free world from peripheral nerve damage supported by Hamilton’s life science ecosystem

August 25, 2023

Epineuron's dedication to advancing nerve regeneration will revolutionize the field and change the standard of care when dealing with nerve injuries

Innovation Factory | Epineuron
MedTech Innovator | Epineuron

Epineuron Chosen as One of 50 Startups for Prestigious MedTech Innovator Program

June 7, 2022

Epineuron's inclusion in the MedTech Innovator program cements the startup's status as a frontrunner in the peripheral nerve industry.

Epineuron Presents at 2022 ASPN Annual Meeting

January 16, 2022

Epineuron presented findings at the American Society for Peripheral Nerve on their clinical implementation of a novel nerve stimulator. The study shows that the device is safe, reliable, and well-tolerated by patients. The study's success paves the way for future larger trials.

ASPN | Epineuron
Finance Closing | Epineuron

Epineuron Closing Financing for Novel Device

May 28, 2020

Epineuron completed a financing round to support the development of its breakthrough neuroregenerative technology. Funding was led by strategic investors including Ontario Centers for Excellence (OCE) and the Ontario Brain Institute (OBI).

Epineuron Receives First Patent Issuance for Peripheral Nerve Regeneration Technology

March 17, 2020 

Epineuron has been granted its first patent for its groundbreaking peripheral nerve regeneration technology, solidifying its position as a leader in the field and paving the way for transformative therapies in nerve repair.

First Patent Issuance for Peripheral Nerve Regeneration Technology | Epineuron
Synapse Competition Winner | Epineuron

Winner of Synapse Competition Grand Prize

March 27, 2019 

Epineuron wins the grand prize at the sixth annual Synapse Life Science Competition, beating out 14 other finalists. Ontario's top life science pitch contest by Innovation Factory, supports innovators and offers resources to bring their products to the market.

Co-founders Featured on the ZoneCast Podcast

March 4, 2019

The ZoneCast hosts interview Sergio Aguirre and Dr. Mike Willand. The co-founders discuss how the therapy works, share results from pre-clinical trials, and show their journey on achieving FDA breakthrough device designation.

ZoneCast Podcast | Epineuron
FDA Breakthrough Device | Epineuron

Epineuron Granted FDA Breakthrough Device Designation 

June 1st, 2018

In recognition of the technology to address an unmet clinical need, Peripulse has been designated a Breakthrough Device from the FDA. Epineuron is the first Canadian company to receive the designation. 

Careers at Epineuron


Join our team on its mission to revolutionize nerve recovery.

Contact Us at Epineuron

Contact Us

Learn more about our technology or research opportunities at Epineuron.

bottom of page